Aveanna Healthcare: $225 Million in Profit — and Nobody Wired $118 Million of It

Everyone knows the feeling. You reach into the pocket of a jacket that has hung in the closet for a year and pull out a $118 gift card. For a moment you feel richer. You are not — your wallet weighs exactly what it weighed before. You have merely rediscovered something you had written off. Call it the gift card trap: we mistake the recovery of a claim for income. That reach into the old jacket is what happened at Aveanna Healthcare Holdings Inc. (Nasdaq: AVAH) in fiscal 2025 — except the amount was $118.1 million, and the find landed directly on the profit line. The stock sits at rank 42 in our in-house Big Earnings Surprise ranking (U.S. selection, 81 hits, as of July 25, 2026). Before the headline number blocks the view, let us make a deal: we read the annual report on Form 10-K for fiscal 2025, the quarterly report on Form 10-Q for the period ended April 4, 2026, and the current reports on Form 8-K through early June 2026 together — and separate cleanly what was earned from what was booked. Remember the line from the start: a profit that comes out of the tax line comes exactly once.

Contents

• What Aveanna actually does
• How the stock reached our desk
• The numbers over the years — fairly credited
• What the filings say: five uncomfortable truths
• What the stock costs — and what that price assumes
• Opportunities and risks at a glance
• A human conclusion
• Sources

What Aveanna actually does — the intensive care unit that comes home

Aveanna Healthcare, based in Atlanta, Georgia, earns its money doing something few people think about until it hits their own family: in-home intensive nursing for critically ill children. A child with a tracheostomy and a ventilator, with cystic fibrosis, with cerebral palsy or after an anoxic brain injury needs a trained nurse around the clock. That care can happen in a hospital — or in a bedroom. Aveanna sends registered and licensed practical nurses into the home, and in some cases along to school. In plain language: Aveanna moves the intensive care unit into the child\'s bedroom, because that is better for the family and cheaper for the payer. By its own account, the company is the largest provider of this service in the United States.

The business stands on three legs. By far the largest is Private Duty Services (PDS) — the skilled nursing described above, plus pediatric therapy (physical, occupational, speech), care in pediatric day health centers, and non-clinical personal care for people with disabilities. One striking detail from the annual report: patients enter the program as children and often stay for years — roughly 30 percent of private duty nursing patients are over the age of 18. The second leg, Home Health & Hospice (HHH), serves mainly older patients at home and accompanies the dying. The third, Medical Solutions (MS), delivers enteral nutrition and medical supplies to the home.

People are the product. As of January 3, 2026, 32,000 people worked for Aveanna, roughly 3,500 of them full-time support staff; the large remainder are caregivers working part-time, per diem or on a temporary basis. That is also where the first fault line runs, and the company names it itself:

"Currently, we are experiencing a shortage of licensed clinicians, which has impacted our industry in general."

— Aveanna Healthcare Holdings Inc., Form 10-K for fiscal 2025, Item 1 "Business"

The work is paid for almost entirely by government. Aveanna bills more than 1,500 distinct payers, yet the origin of the money is unambiguous — which sets the central tension of this analysis, running through every chapter that follows: a business whose prices are set by legislatures, and whose fiscal 2025 profit came half out of a tax entry, has to be read differently from a company that writes its own invoices.

How the stock reached our desk — rank 42 out of 81

We run several thousand stocks through our scanners every day. As of July 25, 2026, Aveanna appears at rank 42 of the 81 U.S. hits in the Big Earnings Surprise ranking, with a relative strength rating of 65 out of 100 — meaning the stock outperformed 65 percent of all tracked names over twelve months, which is solid rather than outstanding. To repeat it yourself: open the scanner, set the country filter to U.S., read the list from the top. The rankings are recalculated daily, so today\'s rank says nothing about tomorrow\'s.

The filter\'s condition is strict and easy to check: reported earnings per share must have exceeded the analyst estimate by at least 20 percent in each of the last four completed quarters. For Aveanna the run looks like this (fundamental data, as of July 25, 2026): plus 47.8 percent for the quarter ended March 31, 2026 ($0.18 versus $0.12 expected), plus 28.9 percent (December 31, 2025), plus 87.5 percent (September 30, 2025) and plus 1,500 percent (June 30, 2025 — $0.16 versus $0.01 expected). Four consecutive quarters comfortably over the bar.

And here is the point you need before the streak impresses you: those surprises measure the adjusted earnings figure, not the tax benefit. Analysts estimate adjusted earnings per share; Aveanna beat them because the operating business genuinely improved. The $118.1 million tax benefit, by contrast, sits inside the reported number — precisely the figure a screen scraper uses to compute a price-earnings ratio. Two different numbers, two different stories. Remember: the surprise is real; the price-earnings ratio next to it is not.

The numbers over the years — fairly credited

First what genuinely speaks for Aveanna, and it is more than the tax objection suggests. Revenue in fiscal 2025 rose 20.2 percent to $2,433.2 million (prior year: $2,024.5 million). The driver was skilled nursing: the PDS segment added $366.5 million, or 22.4 percent — 11.0 percent from more hours delivered and 11.4 percent from higher reimbursement rates granted by various state Medicaid programs. Gross margin climbed from 31.4 percent to 33.3 percent, and operating income went from $139.8 million to $256.5 million (10.5 percent of revenue, up from 6.9 percent).

More telling still is the number the company itself uses to steer the business. Adjusted EBITDA — earnings before interest, taxes, depreciation, amortization and one-off items, roughly what the ongoing operation throws off before the cost of capital — rose 74.8 percent to $320.9 million, moving from 9.1 to 13.2 percent of revenue. And it did not stay a computed figure: operating cash flow, the money that actually arrived from the business, grew from $32.6 million to $125.9 million. Anyone doubting the turnaround needs a good argument at this point.

The debt side improved as well. On September 17, 2025 the company refinanced its credit facilities and repaid a second lien term loan of $415.0 million in full; interest expense fell from $156.6 million to $140.1 million. The weighted average interest rate dropped from 9.0 percent (March 29, 2025) to 7.3 percent (April 4, 2026). On May 26, 2026 Aveanna went further:

"The Amendment constitutes a repricing of the facilities under the Existing Credit Agreement resulting in a 0.50% reduction to applicable interest rate margins."

— Aveanna Healthcare Holdings Inc., Form 8-K dated May 28, 2026, Item 8.01

On the repriced term loans of $1,318.375 million, half a percentage point is roughly $6.6 million less interest a year — and another 0.25 points follow once a rating agency assigns at least a B2 or B. The first quarter of 2026 continued the trend: revenue of $647.9 million (up 15.9 percent), operating income of $69.3 million (up 33.8 percent), adjusted EBITDA of $84.4 million (up 25.2 percent).

And then comes the line this analysis is about. Here is how $256.5 million of operating income became $225.0 million of net income:

What the filings say: five uncomfortable truths

Uncomfortable truth No. 1: more than half of the annual profit is an accounting entry

Pre-tax income in fiscal 2025 was $106.9 million. The bottom line said $225.0 million. The difference is not income but an income tax benefit of $118.1 million — created because Aveanna released valuation allowances on deferred tax assets. Translated into everyday terms: the company had written old tax credits down to a token value because it did not expect ever to use them. In 2025 it concluded that it would use them after all, and wrote them back up. The gift card in the old jacket. The valuation allowance fell from $243.0 million to $104.2 million as a result.

That no money changed hands is written plainly in the cash flow statement: to get from net income to actual operating cash flow, Aveanna subtracts $143.0 million of "deferred income taxes" again — a non-cash item. What remains is $125.9 million of operating cash flow. And the company itself does the adjustment for you: $1.05 per diluted share under accounting rules, $0.60 adjusted.

The first quarter of 2026 supplies the control test. There was no tax benefit in the books, but $3.3 million of income tax expense. Reported $0.19, adjusted $0.18 per share — the two numbers are back together. The gift card was a one-off.

Uncomfortable truth No. 2: the record year had one week more than the year before

Aveanna does not count in calendar years but in weeks — and every few years an extra one fits in. That is exactly what happened in 2025:

It sounds like bookkeeping, but it shifts every growth figure. A 53rd week is about 1.9 percent more time — so of the 20.2 percent revenue growth in fiscal 2025, roughly 18 percent is genuine expansion. The effect is even clearer in the final quarter: the fourth quarter of 2025 covered 14 weeks versus 13 the year before, and that very quarter reported 27.4 percent revenue growth. About a seventh of that jump is simply the extra block of days. Anyone extrapolating the trend should measure against the full-year figure, not that quarter — in the first quarter of 2026, back to normal length, growth was 15.9 percent.

Uncomfortable truth No. 3: legislatures decide 81.5 percent of revenue

Aveanna does not set its own prices. The revenue table in the notes to the annual report allocates fiscal 2025 revenue as follows: 58.7 percent Medicaid managed care, 22.8 percent traditional Medicaid, 9.9 percent Medicare, 8.5 percent commercial insurers, 0.1 percent self-pay. Added up: 81.5 percent from Medicaid, the public health program for people on low incomes, and 91.4 percent from public programs in total. The prior-year comparison: 79.9 percent Medicaid — so the dependency has grown.

What that means shows up a few pages later in the same filing. The U.S. Centers for Medicare & Medicaid Services initially proposed cutting home health payments by 6.4 percent for 2026 and settled at minus 1.3 percent in the final rule. And for Medicaid, a larger number is on the table:

"The Congressional Budget Office projects OBBBA will result in a reduction to federal Medicaid spending by an estimated $1.15 trillion over the next ten years."

— Aveanna Healthcare Holdings Inc., Form 10-K for fiscal 2025, "Regulatory Developments"

Aveanna adds that most of the applicable provisions take effect on December 31, 2026 or later and that it does not believe its own services are directly affected — but that tighter state budgets may indirectly slow future rate increases. That is exactly where the risk sits: of the fiscal 2025 revenue jump, 11.4 percentage points came from higher rates. Take that tailwind away and only volume growth is left.

Uncomfortable truth No. 4: a profitable year — and still $1.48 billion of debt

The turnaround did not heal the balance sheet; it merely pushed it back above zero. As of April 4, 2026, $1,483.4 million of debt stood against $240.1 million of equity; a year earlier equity was negative. The accumulated deficit of the company\'s history still stands at $1,115.5 million. And of the $2,022.0 million of total assets, $1,121.0 million is goodwill and $91.9 million is other intangibles — together roughly 60 percent, positions that cannot be sold.

Measured against the company\'s own 2026 guidance — adjusted EBITDA of $338 million to $342 million, as of June 2, 2026 — that is a good four to four and a half times annual earnings power. It is within what lenders in this sector accept, but it leaves little room. A second point comes on top: in the first quarter of 2026, operating cash flow was only $4.3 million and free cash flow was negative $3.8 million — in the same quarter that reported $41.7 million of net income. The causes are seasonal payouts and growing receivables ($332.7 million as of April 4, 2026, up from $313.4 million at year end). Remember: a quarter with profit and no cash is normal in this business model — but only if the cash arrives later. And on June 1, 2026, $175.5 million in cash went out for the Family First Homecare acquisition, from a balance that stood at $189.3 million on April 4.

Uncomfortable truth No. 5: the share count grows faster than earnings

Dilution means your slice of the cake gets smaller without the cake getting bigger. At Aveanna it moves quickly. As of January 3, 2026 there were 210,996,359 shares, as of April 4, 2026 already 217,510,046, and as of May 8, 2026 217,755,203. Of the 6,513,687 new shares in the first quarter, 6,458,687 came from vested restricted shares and 55,000 from options; the cash that arrived was $269,000. In a single quarter, every existing shareholder\'s slice shrank by roughly 3.1 percent.

The pipeline is not empty either. As of January 3, 2026 there were 12,995,652 options outstanding at a weighted average exercise price of $6.41, 7,540,876 of them exercisable, plus 15,617,361 restricted stock units. Together, 28.6 million potential new shares — a good 13 percent of the count. There was a preview in 2025: for the acquisition of competitor Thrive Skilled Pediatric Care on June 2, 2025, Aveanna paid $75.7 million, of which only $15.9 million was cash — the rest was 11.2 million new shares worth $59.8 million. To its credit, Family First was paid for entirely in cash a year later. If you want the comparison case where an entire equity swing came from a single accounting entry, it is in our Battalion Oil analysis.

What the stock costs — and what that price assumes

And here the circle back to the gift card trap closes, because the trap sits inside the valuation. As of July 25, 2026, Aveanna carries a market value of roughly $2.06 billion on 217,755,203 shares (as of May 8, 2026). A screen shows a price-earnings ratio of 7.5 alongside it — calculated on $1.26 of trailing twelve-month earnings per share. That figure contains the tax benefit. Use the adjusted fiscal 2025 result of $0.60 instead and the ratio is about 16. Analysts expect $0.71 per share for the current year, which puts the ratio near 12 (fundamental data, as of July 25, 2026). Remember: a single-digit price-earnings ratio produced by a tax entry is not a margin of safety; it is an arithmetic error with a date stamp.

The other orders of magnitude, same as-of date: revenue is valued at 0.8 times, book value at 8.2 times — the latter only because equity turned positive again in 2025. More meaningful is enterprise value, that is market value plus debt less cash: roughly $3.29 billion, or 9.6 to 9.7 times the adjusted EBITDA of $338 million to $342 million guided for 2026. That is neither cheap nor expensive — it is the price of a leveraged service provider whose customer is the state.

The professionals\' view fits that. Eight analysts cover the stock: one strong buy, five holds, one sell and one strong sell, with an average price target of $10.45 (fundamental data, as of July 25, 2026). As a dated valuation anchor from a primary document, the prospectus supplement of October 21, 2025 names the last reported sale price of the stock at $10.23 — while placing 10.0 million shares for existing holders at $9.00. If you want to see what a turnaround under a heavy debt load looks like over several years, there is a second example in our Sirius XM analysis.

A word on the owners, because it explains how the stock trades: Bain Capital and J.H. Whitney together held 57.7 percent of the shares as of January 3, 2026, so Aveanna qualifies as a "controlled company" under Nasdaq rules and need not have a majority of independent directors. The proxy statement as of April 6, 2026 lists Bain at 37.5 percent and Whitney at 18.4 percent. The freely traded portion is correspondingly small — about 87 million shares, a good 40 percent of the count (fundamental data, as of July 25, 2026).

Opportunities and risks at a glance

What speaks for Aveanna:

• The operating turn is documented, not asserted. Adjusted EBITDA up 74.8 percent to $320.9 million in fiscal 2025, operating cash flow from $32.6 million to $125.9 million, operating margin from 6.9 to 10.5 percent.
• Structural tailwind. Care at home is cheaper for payers than a hospital or nursing facility; Aveanna is, by its own account, the largest U.S. provider of pediatric private duty nursing and adds growth through acquisitions (Thrive in 2025, Family First in 2026).
• Interest costs are falling to plan. The $415.0 million second lien loan was repaid in September 2025, margins were cut by 0.50 percentage points in May 2026 with another 0.25 points available on a better rating; the average rate fell from 9.0 to 7.3 percent.
• Interest rate risk partly hedged. As of April 4, 2026 the company held interest rate swaps with a notional amount of $520.0 million and caps of $880.0 million with a SOFR ceiling of 2.96 percent.

What speaks against it:

• More than half of the reported fiscal 2025 profit is a tax entry — $118.1 million out of $225.0 million. Every metric built on reported earnings per share is flattered as a result.
• 81.5 percent of revenue depends on Medicaid, 91.4 percent on public programs. The Congressional Budget Office projects $1.15 trillion less federal Medicaid spending over ten years.
• High leverage against thin equity. $1,483.4 million of debt versus $240.1 million of equity as of April 4, 2026; roughly 60 percent of total assets are goodwill and intangibles.
• Ongoing dilution. 6,513,687 new shares in the first quarter of 2026 for $269,000 of cash received, plus 28.6 million options and restricted stock units outstanding.
• Labor shortage as a growth brake. The company reports a shortage of licensed clinicians itself; the business grows only as fast as caregivers can be hired.
• Two large holders with 55.9 percent (as of April 6, 2026) and a history of placements — in October 2025 existing holders sold 10.0 million shares at $9.00.

A human conclusion

Back to the old jacket. The $118 gift card was real — it truly was in the pocket, it truly had value, and finding it is a good day. It is just not a salary. It does not come back every month, and you cannot build your life around it. That is exactly how Aveanna\'s fiscal 2025 profit works: the $118.1 million tax benefit is neither a trick nor cosmetic accounting but a correct entry that even carries good news — the company now believes it will earn enough to use old tax credits. But it is a one-off, and the first quarter of 2026 has already proved it.

What remains once you take the gift card back out of the calculation is still remarkable: a company that was in the red in 2024, that has nearly doubled its margin in two years, that has shed its most expensive debt, and that works in a field where demand will not disappear. Next to it stands a company whose prices are set by legislatures, that carries $1.48 billion of debt, and that pays its own people with shares that belong to you.

Both are true. Anyone investing here really decides only one question: do you believe adjusted earnings will grow, over the next few years, to where the reported figure already stood once in 2025? We have shown you the numbers to check that with — the tax rate, free cash flow, the share count on the cover page. What you do with them is your decision. And that is exactly as it should be.

Sources

• Form 10-K for fiscal 2025 (53 weeks, ended January 3, 2026), filed March 19, 2026: sec.gov
• Form 10-K for fiscal 2024 (ended December 28, 2024), filed March 13, 2025: sec.gov
• Form 10-Q for the quarter ended April 4, 2026, filed May 14, 2026: sec.gov
• Form 8-K dated May 14, 2026 (first quarter results and 2026 guidance): sec.gov
• Form 8-K dated May 28, 2026 (repricing, $1,318.375 million of 2026 term loans): sec.gov
• Form 8-K dated June 2, 2026 (completion of Family First Homecare, $175.5 million, updated guidance): sec.gov
• Form 8-K dated March 12, 2026 (purchase agreement for Family First Homecare): sec.gov
• Proxy statement DEF 14A 2026, filed April 17, 2026 (ownership as of April 6, 2026): sec.gov
• Prospectus supplement 424B4 dated October 21, 2025 (placement of 10.0 million shares at $9.00; last reported sale price $10.23 on October 21, 2025): sec.gov
• Screening, valuation and analyst data: our in-house stock scanner and fundamental data (as of July 25, 2026), including the Big Earnings Surprise ranking (U.S. selection, rank 42 of 81 hits, RS rating 65); the lists are recalculated daily.

Disclaimer: This article is journalistic analysis of publicly available documents. It is not investment advice, not a recommendation to buy or sell, and not a solicitation to buy or sell securities. Equity investments can result in a total loss. All figures are taken from the SEC filings named above or from fundamental data with the as-of date stated in each case, and may have changed since. The author holds no position in Aveanna Healthcare Holdings Inc. at the time of publication.